

Resource Summary Report

Generated by [NIF](#) on Aug 4, 2026

LNCaP

RRID:CVCL_0395

Type: Cell Line

Proper Citation

RRID:CVCL_0395

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0395

Proper Citation: RRID:CVCL_0395

Description: Cell line LNCaP is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Prostate carcinoma

Defining Citation: [PMID:2734981](#), [PMID:3335022](#), [PMID:3518877](#), [PMID:6831420](#), [PMID:8687134](#), [PMID:9018337](#), [PMID:9090379](#), [PMID:9460501](#), [PMID:10702678](#), [PMID:10972993](#), [PMID:11135431](#), [PMID:11172901](#), [PMID:11304728](#), [PMID:11414198](#), [PMID:11416159](#), [PMID:12606952](#), [PMID:12725112](#), [PMID:14518029](#), [PMID:15162376](#), [PMID:15486987](#), [PMID:22213130](#), [PMID:22278370](#), [PMID:23671654](#), [PMID:24587179](#), [PMID:24618588](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26256267](#), [PMID:26589293](#), [PMID:26972028](#), [PMID:27036029](#), [PMID:27141528](#), [PMID:29194687](#), [PMID:29233929](#), [PMID:29660373](#), [PMID:29739788](#), [PMID:30787054](#), [PMID:35502546](#), [PMID:38892296](#)

Comments: Population: Caucasian., Part of: ENCODE project common cell types; tier 3., Group: Space-flown cell line (cellonaut).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LNCaP

Synonyms: LNCAP, LNCap, Ln-Cap, LNCaP-RPCI, Lymph Node Carcinoma of the prostate

Cross References: BTO:BTO_0001321, CLO:CLO_0007365, CLO:CLO_0037116, EFO:EFO_0002071, MCCL:MCC:0000290, CLDB:cl3243, ArrayExpress:E-MTAB-2706,

BioGRID_ORCS_Cell_line:182, BioSample:SAMN03472386, cancercellines:CVCL_0395, CCRID:1101HUM-PUMC000040, CCTCC:GDC0283, CCTCC:GDC0284, ChEMBL-Cells:ChEMBL3307965, ChEMBL-Targets:ChEMBL612518, CLS:300265, Cosmic:704848, Cosmic:721368, Cosmic:721555, Cosmic:755298, Cosmic:759895, Cosmic:801348, Cosmic:850413, Cosmic:850745, Cosmic:850821, Cosmic:869155, Cosmic:918500, Cosmic:920967, Cosmic:921047, Cosmic:922553, Cosmic:923955, Cosmic:943176, Cosmic:948076, Cosmic:949248, Cosmic:1028648, Cosmic:1028701, Cosmic:1066237, Cosmic:1070886, Cosmic:1071481, Cosmic:1071906, Cosmic:1075275, Cosmic:1172626, Cosmic:1176618, Cosmic:1330909, Cosmic:1556120, Cosmic:1689708, Cosmic:1995486, Cosmic:2537792, Cosmic:2580128, Cosmic:2585151, Cosmic:2585228, Cosmic:2621168, Cosmic:2651770, Cosmic:2669169, Cosmic:2816221, DSMZ:ACC-256, DSMZCellDive:ACC-256, EGA:EGAS00001000610, GEO:GSE99795, GEO:GSM91927, GEO:GSM142457, GEO:GSM142458, GEO:GSM383948, GEO:GSM383953, GEO:GSM482669, GEO:GSM525800, GEO:GSM784790, GEO:GSM816634, GEO:GSM816637, GEO:GSM844579, GEO:GSM945240, GEO:GSM945282, GEO:GSM1022672, GEO:GSM1029460, GEO:GSM1029461, GEO:GSM1029462, GEO:GSM1029463, GEO:GSM1029464, GEO:GSM1029465, GEO:GSM1029466, GEO:GSM1029467, GEO:GSM1374622, GEO:GSM1374626, GEO:GSM2069518, GEO:GSM2069519, GEO:GSM2069520, GEO:GSM2069521, GEO:GSM2069522, GEO:GSM2069523, GEO:GSM2069524, GEO:GSM2069525, GEO:GSM2650017, GEO:GSM2650018, GEO:GSM2650019, GEO:GSM2650020, GEO:GSM2650021, GEO:GSM2650022, GEO:GSM3145602, GEO:GSM3145720, IARC_TP53:21076, LINCS_LDP:LCL-1298, Lonza:109, PharmacDB:LNCAP_850_2019, PRIDE:PXD000953, PRIDE:PXD000985, PRIDE:PXD002107, PRIDE:PXD002395, PRIDE:PXD003105, PRIDE:PXD003262, PRIDE:PXD006561, PRIDE:PXD032264, Progenetix:CVCL_0395, PubChem_Cell_line:CVCL_0395, TOKU-E:3599, Wikidata:Q6459234

ID: CVCL_0395

Record Creation Time: 20220427T220731+0000

Record Last Update: 20260802T002156+0000

Ratings and Alerts

No rating or validation information has been found for LNCaP.

No alerts have been found for LNCaP.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 3145 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Portman N, et al. (2026) Characterising the effect of circulating sphingolipids on metastatic prostate cancer cells. *EBioMedicine*, 123, 106058.

Zhou Y, et al. (2026) Distinct Regulation of the ARF and TAp73 Tumor Suppressor Genes by the Transcription Factor E2F1 Enables Discrimination of Cancer Cells from Normal Growing Cells. *Cells*, 15(1).

Al-Mathkour MM, et al. (2026) The YAP1 and EPHA3 receptor tyrosine kinase axis regulates cellular plasticity and treatment response. *Cellular signalling*, 141, 112368.

Ma S, et al. (2025) Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer. *Cancer research*, 85(19), 3771.

Phung SK, et al. (2025) A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer. *Cancer immunology research*, 13(2), 258.

Bidkar AP, et al. (2025) Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(14), 2963.

Kasama H, et al. (2025) Laeverin is Cell-Surface Target for Liquid-Phase Metastasizing Cancer Cells. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(47), e11349.

Gui F, et al. (2025) Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancer. *Science advances*, 11(17), eadu0847.

Sawada Y, et al. (2025) CTHRC1 promotes bone metastasis in prostate cancer. *International journal of cancer*.

Yang W, et al. (2025) Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors. *Science advances*, 11(29), eadw5228.

Morozova V, et al. (2025) Pharmacodynamic analyses of LAT1 inhibitors in vitro and in vivo by targeted metabolomics reveal target-independent effects. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 190, 118402.

Kirthika P, et al. (2025) Off-pore Nucleoporin sPOM121 Transcriptionally Propels β -Catenin-driven Tumor Progression and Immune Escape in Prostate Cancer. *Cancer discovery*, 15(11), 2374.

Dathathri E, et al. (2025) Secretome Analysis of Prostate Cancer Cell Lines Reveals Cell Cycle-Dependent PSA Secretion and Potential Biomarkers. *Cancers*, 17(5).

Wang H, et al. (2025) Integrated Analysis of Single-Cell RNA Sequencing and Machine Learning Reveals a T Cell-Specific PANoptosis Signature Predicting Prognosis and Immunotherapy in Prostate Cancer. *Human mutation*, 2025, 8889021.

Leslie AR, et al. (2025) IGFBP3-SphK1/S1P Signaling Axis Drives Enzalutamide Resistance in Advanced Prostate Cancer. *Molecular cancer therapeutics*.

Zhang L, et al. (2025) Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer. *Cancer research*, 85(1), 134.

Kumar R, et al. (2025) CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptor. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 39(2), e70342.

Cohen A, et al. (2025) Applying Unbiased, Functional Criteria Allows Selection of Novel Cyclic Peptides for Effective Targeted Drug Delivery to Malignant Prostate Cancer Cells. *Pharmaceutics*, 17(7).

Li S, et al. (2025) Defined cellular reprogramming of androgen receptor-active prostate cancer to neuroendocrine prostate cancer. *bioRxiv : the preprint server for biology*.

Kumaraswamy A, et al. (2025) Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer. *NPJ precision oncology*, 9(1), 223.